Literature DB >> 20555148

CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease.

Jeroen J J van Eijk1, Bart van Everbroeck, W Farid Abdo, Berry P H Kremer, Marcel M Verbeek.   

Abstract

In this study we investigated the cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and heavy chain (NFHp35), total tau (t-tau), and glial fibrillary acidic protein (GFAP) to detect disease specific profiles in sporadic Creutzfeldt Jakob disease (sCJD) patients and Alzheimer's disease (AD) patients. CSF levels of NFL, NFHp35, t-tau, and GFAP of 23 sCJD patients and 55 AD patients were analyzed and compared to non-demented controls. Median NFL, NFHp35, GFAP, and t-tau levels were significantly increased in sCJD patients and AD patients versus controls (p < 0.0001 in all). NFL, NFHp35, and t-tau levels were significantly increased in sCJD patients versus AD patients (p < 0.005), but GFAP concentrations did not differ between sCJD and AD. The results suggest that neuroaxonal damage, reflected by higher CSF levels of NFL, NFHp35, and t-tau, is more pronounced in the pathophysiology of sCJD than in AD. The comparable CSF GFAP concentrations suggest that astroglial damage or astrocytosis is equally pronounced in the pathophysiology of AD and sCJD. Prospective studies are needed to determine whether NFL and NFHp35 may be additional tools in the differential diagnosis of rapidly progressive dementias.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20555148     DOI: 10.3233/JAD-2010-090649

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  21 in total

1.  Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease.

Authors:  Gajanan Sathe; Chan Hyun Na; Santosh Renuse; Anil K Madugundu; Marilyn Albert; Abhay Moghekar; Akhilesh Pandey
Journal:  Proteomics Clin Appl       Date:  2019-01-25       Impact factor: 3.494

Review 2.  Paving the path to HIV neurotherapy: Predicting SIV CNS disease.

Authors:  Sarah E Beck; Suzanne E Queen; Kenneth W Witwer; Kelly A Metcalf Pate; Lisa M Mangus; Lucio Gama; Robert J Adams; Janice E Clements; M Christine Zink; Joseph L Mankowski
Journal:  Eur J Pharmacol       Date:  2015-03-24       Impact factor: 4.432

Review 3.  Applying fluid biomarkers to Alzheimer's disease.

Authors:  Henrik Zetterberg
Journal:  Am J Physiol Cell Physiol       Date:  2017-04-19       Impact factor: 4.249

4.  Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants.

Authors:  Davide Bruno; Nunzio Pomara; Jay Nierenberg; James C Ritchie; Michael W Lutz; Henrik Zetterberg; Kaj Blennow
Journal:  Exp Gerontol       Date:  2011-10-01       Impact factor: 4.032

Review 5.  Recent advances in phosphoproteomics and application to neurological diseases.

Authors:  Justine V Arrington; Chuan-Chih Hsu; Sarah G Elder; W Andy Tao
Journal:  Analyst       Date:  2017-11-20       Impact factor: 4.616

6.  Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie.

Authors:  Marina Betancor; Sonia Pérez-Lázaro; Alicia Otero; Belén Marín; Inmaculada Martín-Burriel; Kaj Blennow; Juan José Badiola; Henrik Zetterberg; Rosa Bolea
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

Review 7.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Anne M Fagan; Richard J Perrin
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

Review 8.  Neurofilaments in disease: what do we know?

Authors:  Brian A Gordon
Journal:  Curr Opin Neurobiol       Date:  2020-03-06       Impact factor: 6.627

Review 9.  Clinical Use of Improved Diagnostic Testing for Detection of Prion Disease.

Authors:  Mark P Figgie; Brian S Appleby
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

10.  Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS.

Authors:  Ching-Hua Lu; Axel Petzold; Bernadett Kalmar; James Dick; Andrea Malaspina; Linda Greensmith
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.